Basic Study
Copyright ©The Author(s) 2024.
World J Gastrointest Oncol. Feb 15, 2024; 16(2): 475-492
Published online Feb 15, 2024. doi: 10.4251/wjgo.v16.i2.475
Figure 2
Figure 2 Association analysis of B56ε expression with tumor mutations, somatic copy number alterations, and immunity in pan-cancer. A: Percentage of samples with B56ε mutation; B: Somatic copy number alterations by the Tumor Immune Estimation Resource database; C: Associations between B56ε expression and estimate score, immune score, and stromal score in different cancers; D: Correlation analysis between immune checkpoint genes and the expression of B56ε. aP < 0.05; bP < 0.01; cP < 0.001. sCNA: Somatic copy number alteration; ACC: Adrenocortical carcinoma; BLCA: Bladder urothelial carcinoma; BRCA: Breast invasive carcinoma; CESC: Cervical squamous cell carcinoma; CHOL: Cholangiocarcinoma; COAD: Colon adenocarcinoma; DLBC: Lymphoid neoplasm diffuse large B cell lymphoma; ESCA: Esophageal carcinoma; GBM: Glioblastoma; HNSC: Head and neck squamous cell carcinoma; KICH: Kidney chromophobe; KIRP: Kidney renal papillary cell carcinoma; KIRC: Kidney clear cell carcinoma; LGG: Low-grade glioma; LIHC: The Cancer Genome Atlas-Liver hepatocellular carcinoma; LUAD: Lung adenocarcinoma; LUSC: Lung squamous cell carcinoma; MESO: Mesothelioma; OV: Ovarian serous cystadenoma; PAAD: Pancreatic adenocarcinoma; PCPG: Pheochromocytoma and paraganglioma; PRAD: Prostate adenocarcinoma; READ: Rectal adenocarcinoma; SARC: Sarcoma; SKCM: Skin cutaneous melanoma; STAD: Stomach adenocarcinoma; TGCT: Testicular germ cell tumor; THCA: Thyroid carcinoma; THYM: Thymic carcinoma; UCEC: Endometrial cancer; UCS: Uterine carcinosarcoma; UVM: Uveal melanoma.